In prostate cancer, FAP+ stromal programmes co‐occur with immunosuppressive myeloid states (e.g., CD163+/SPP1+ macrophages) [54] and FAP itself can also promote macrophage activation and tissue remodelling [55]. This evidence concerns the gene CD163 and prostate carcinoma.